TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06087653: Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Sponsor: Starton Therapeutics, Inc · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 24 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$8,246,700

Rescue Site Savings

+$5,458,530

Unlock Full NCT06087653 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06087653 Rescue Dossier →